Acasti Pharma Inc (NASDAQ:ACST) – Research analysts at Oppenheimer issued their Q1 2021 earnings estimates for shares of Acasti Pharma in a research note issued to investors on Thursday, November 14th. Oppenheimer analyst L. Gershell expects that the biopharmaceutical company will earn ($0.10) per share for the quarter. Oppenheimer also issued estimates for Acasti Pharma’s Q2 2021 earnings at ($0.10) EPS, Q3 2021 earnings at ($0.11) EPS, Q4 2021 earnings at ($0.11) EPS and FY2023 earnings at $0.74 EPS.
ACST has been the topic of a number of other reports. B. Riley began coverage on shares of Acasti Pharma in a research note on Thursday, August 29th. They issued a “buy” rating and a $7.75 price objective on the stock. ValuEngine cut shares of Acasti Pharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 8th. Zacks Investment Research cut shares of Acasti Pharma from a “hold” rating to a “sell” rating in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating on shares of Acasti Pharma in a research note on Thursday, August 15th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $6.05.
Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Investment Advisors Ltd. acquired a new stake in Acasti Pharma in the 3rd quarter valued at about $38,000. Morgan Stanley boosted its stake in shares of Acasti Pharma by 20.6% during the 2nd quarter. Morgan Stanley now owns 45,687 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 7,789 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. acquired a new stake in shares of Acasti Pharma during the 3rd quarter worth about $95,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Acasti Pharma during the 3rd quarter worth about $104,000. Finally, Bank of Montreal Can boosted its stake in shares of Acasti Pharma by 2.0% during the 2nd quarter. Bank of Montreal Can now owns 253,287 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 5,000 shares during the last quarter. 3.12% of the stock is currently owned by hedge funds and other institutional investors.
Acasti Pharma Company Profile
Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.
Further Reading: How to Invest in Growth Stocks
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.